WallStreetZenWallStreetZen

NASDAQ: CNTA
Centessa Pharmaceuticals PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CNTA

Based on 4 analysts offering 12 month price targets for Centessa Pharmaceuticals PLC

Min Forecast
$27.00+116.69%
Avg Forecast
$30.75+146.79%
Max Forecast
$38.00+204.98%

Should I buy or sell CNTA stock?

Based on 4 analysts offering ratings for Centessa Pharmaceuticals PLC.

Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CNTA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CNTA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CNTA stock forecasts and price targets.

CNTA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-08
lockedlocked$00.00+00.00%2025-03-31
lockedlocked$00.00+00.00%2025-03-26
lockedlocked$00.00+00.00%2025-03-07

1 of 1

Forecast return on equity

Is CNTA forecast to generate an efficient return?

Company
-47.21%
Industry
138.99%
Market
90.49%
CNTA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CNTA forecast to generate an efficient return on assets?

Company
-32.86%
Industry
36.84%
CNTA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CNTA earnings per share forecast

What is CNTA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.48
Avg 2 year Forecast
-$1.58
Avg 3 year Forecast
-$1.67

CNTA revenue forecast

What is CNTA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$50.8M
Avg 2 year Forecast
$182.0M
Avg 3 year Forecast
$68.8M

CNTA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CNTA$12.46$30.75+146.79%Strong Buy
AGIO$28.74$62.00+115.73%Buy
ARQT$13.82$18.80+36.03%Buy
IRON$46.35$104.00+124.38%Strong Buy
TARS$41.46$66.33+59.99%Strong Buy
View Top Biotech Stocks

Centessa Pharmaceuticals Stock Forecast FAQ

Is Centessa Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CNTA) stock is to Strong Buy CNTA stock.

Out of 4 analysts, 4 (100%) are recommending CNTA as a Strong Buy, 0 (0%) are recommending CNTA as a Buy, 0 (0%) are recommending CNTA as a Hold, 0 (0%) are recommending CNTA as a Sell, and 0 (0%) are recommending CNTA as a Strong Sell.

If you're new to stock investing, here's how to buy Centessa Pharmaceuticals stock.

What is CNTA's earnings growth forecast for 2025-2027?

(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.88%.

Centessa Pharmaceuticals's earnings in 2025 is -$235,757,000.On average, 6 Wall Street analysts forecast CNTA's earnings for 2025 to be -$196,446,915, with the lowest CNTA earnings forecast at -$217,090,489, and the highest CNTA earnings forecast at -$161,153,062. On average, 5 Wall Street analysts forecast CNTA's earnings for 2026 to be -$210,697,640, with the lowest CNTA earnings forecast at -$267,700,541, and the highest CNTA earnings forecast at -$147,834,627.

In 2027, CNTA is forecast to generate -$222,950,600 in earnings, with the lowest earnings forecast at -$310,319,533 and the highest earnings forecast at -$137,179,879.

What is CNTA's revenue growth forecast for 2026-2028?

(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.71%.

Centessa Pharmaceuticals's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast CNTA's revenue for 2026 to be $6,771,225,488, with the lowest CNTA revenue forecast at $6,217,311,780, and the highest CNTA revenue forecast at $7,325,139,195. On average, 1 Wall Street analysts forecast CNTA's revenue for 2027 to be $24,239,551,518, with the lowest CNTA revenue forecast at $24,239,551,518, and the highest CNTA revenue forecast at $24,239,551,518.

In 2028, CNTA is forecast to generate $9,163,083,211 in revenue, with the lowest revenue forecast at $8,603,708,945 and the highest revenue forecast at $9,722,457,477.

What is CNTA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CNTA) forecast ROA is -32.86%, which is lower than the forecast US Biotechnology industry average of 36.84%.

What is CNTA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CNTA price target, the average CNTA price target is $30.75, with the highest CNTA stock price forecast at $38.00 and the lowest CNTA stock price forecast at $27.00.

On average, Wall Street analysts predict that Centessa Pharmaceuticals's share price could reach $30.75 by May 8, 2026. The average Centessa Pharmaceuticals stock price prediction forecasts a potential upside of 146.79% from the current CNTA share price of $12.46.

What is CNTA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CNTA) Centessa Pharmaceuticals's current Earnings Per Share (EPS) is -$2.06. On average, analysts forecast that CNTA's EPS will be -$1.48 for 2025, with the lowest EPS forecast at -$1.63, and the highest EPS forecast at -$1.21. On average, analysts forecast that CNTA's EPS will be -$1.58 for 2026, with the lowest EPS forecast at -$2.01, and the highest EPS forecast at -$1.11. In 2027, CNTA's EPS is forecast to hit -$1.67 (min: -$2.33, max: -$1.03).

What is CNTA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CNTA) forecast ROE is -47.21%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.